-
Something wrong with this record ?
Weight and metabolic changes in early psychosis-association with daily quantification of medication exposure during the first hospitalization
K. Vochoskova, SR. McWhinney, M. Fialova, M. Kolenic, F. Spaniel, P. Svancer, P. Boron, Y. Okaji, P. Trancik, T. Hajek
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
180449
CIHR - Canada
142255
CIHR - Canada
PubMed
37528692
DOI
10.1111/acps.13594
Knihovny.cz E-resources
- MeSH
- Antipsychotic Agents * adverse effects MeSH
- Weight Gain MeSH
- Hospitalization MeSH
- Humans MeSH
- Metabolic Syndrome * chemically induced epidemiology MeSH
- Psychotic Disorders * drug therapy MeSH
- Schizophrenia * drug therapy MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
BACKGROUND: The most common causes of death in schizophrenia are cardiovascular disorders, which are closely related to metabolic syndrome/obesity. To better understand the development of metabolic alterations early in the course of illness, we quantified daily medication exposure in the first days of the first hospitalization for psychosis and related it to changes in weight and metabolic markers. STUDY DESIGN: We recruited participants with first episode psychosis (FEP, N = 173) during their first psychiatric hospitalization and compared them to controls (N = 204). We prospectively collected weight, body mass index, metabolic markers, and exact daily medication exposure at admission and during hospitalization. STUDY RESULTS: Individuals with FEP gained on average 0.97 ± 2.26 BMI points or 3.46 ± 7.81 kg of weight after an average of 44.6 days of their first inpatient treatment. Greater antipsychotic exposure was associated with greater BMI increase, but only in people with normal/low baseline BMI. Additional predictors of weight gain included type of medication and duration of treatment. Medication exposure was not directly related to metabolic markers, but higher BMI was associated with higher TGC, TSH, and lower HDL. Following inpatient treatment, participants with FEP had significantly higher BMI, TGC, prolactin, and lower fT4, HDL than controls. CONCLUSION: During their first admission, people with FEP, especially those with normal/low baseline BMI, showed a rapid and clinically significant weight increase, which was associated with exposure to antipsychotics, and with metabolic changes consistent with metabolic syndrome. These findings emphasize weight monitoring in FEP and suggest a greater need for caution when prescribing metabolically problematic antipsychotics to people with lower BMI.
3rd Faculty of Medicine Charles University Prague Czech Republic
Department of Psychiatry Dalhousie University Halifax Canada
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23016337
- 003
- CZ-PrNML
- 005
- 20231026110022.0
- 007
- ta
- 008
- 231013s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/acps.13594 $2 doi
- 035 __
- $a (PubMed)37528692
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Vochoskova, Kristyna $u National Institute of Mental Health, Klecany, Czech Republic $u Third Faculty of Medicine, Charles University, Prague, Czech Republic
- 245 10
- $a Weight and metabolic changes in early psychosis-association with daily quantification of medication exposure during the first hospitalization / $c K. Vochoskova, SR. McWhinney, M. Fialova, M. Kolenic, F. Spaniel, P. Svancer, P. Boron, Y. Okaji, P. Trancik, T. Hajek
- 520 9_
- $a BACKGROUND: The most common causes of death in schizophrenia are cardiovascular disorders, which are closely related to metabolic syndrome/obesity. To better understand the development of metabolic alterations early in the course of illness, we quantified daily medication exposure in the first days of the first hospitalization for psychosis and related it to changes in weight and metabolic markers. STUDY DESIGN: We recruited participants with first episode psychosis (FEP, N = 173) during their first psychiatric hospitalization and compared them to controls (N = 204). We prospectively collected weight, body mass index, metabolic markers, and exact daily medication exposure at admission and during hospitalization. STUDY RESULTS: Individuals with FEP gained on average 0.97 ± 2.26 BMI points or 3.46 ± 7.81 kg of weight after an average of 44.6 days of their first inpatient treatment. Greater antipsychotic exposure was associated with greater BMI increase, but only in people with normal/low baseline BMI. Additional predictors of weight gain included type of medication and duration of treatment. Medication exposure was not directly related to metabolic markers, but higher BMI was associated with higher TGC, TSH, and lower HDL. Following inpatient treatment, participants with FEP had significantly higher BMI, TGC, prolactin, and lower fT4, HDL than controls. CONCLUSION: During their first admission, people with FEP, especially those with normal/low baseline BMI, showed a rapid and clinically significant weight increase, which was associated with exposure to antipsychotics, and with metabolic changes consistent with metabolic syndrome. These findings emphasize weight monitoring in FEP and suggest a greater need for caution when prescribing metabolically problematic antipsychotics to people with lower BMI.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a antipsychotika $x škodlivé účinky $7 D014150
- 650 12
- $a metabolický syndrom $x chemicky indukované $x epidemiologie $7 D024821
- 650 12
- $a psychotické poruchy $x farmakoterapie $7 D011618
- 650 12
- $a schizofrenie $x farmakoterapie $7 D012559
- 650 _2
- $a hmotnostní přírůstek $7 D015430
- 650 _2
- $a hospitalizace $7 D006760
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a McWhinney, Sean R $u Department of Psychiatry, Dalhousie University, Halifax, Canada
- 700 1_
- $a Fialova, Marketa $u National Institute of Mental Health, Klecany, Czech Republic $u Third Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Kolenic, Marian $u National Institute of Mental Health, Klecany, Czech Republic $u Third Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Spaniel, Filip $u National Institute of Mental Health, Klecany, Czech Republic $u Third Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/000000033479696X $7 xx0102926
- 700 1_
- $a Svancer, Patrik $u National Institute of Mental Health, Klecany, Czech Republic $u Third Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000167346936
- 700 1_
- $a Boron, Petra $u Psychiatric Hospital Bohnice, Prague, Czech Republic
- 700 1_
- $a Okaji, Yurai $u Psychiatric Hospital Bohnice, Prague, Czech Republic
- 700 1_
- $a Trancik, Pavel $u Psychiatric Hospital Bohnice, Prague, Czech Republic
- 700 1_
- $a Hajek, Tomas $u National Institute of Mental Health, Klecany, Czech Republic $u Third Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Psychiatry, Dalhousie University, Halifax, Canada
- 773 0_
- $w MED00009053 $t Acta psychiatrica Scandinavica $x 1600-0447 $g Roč. 148, č. 3 (2023), s. 265-276
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37528692 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20231013 $b ABA008
- 991 __
- $a 20231026110017 $b ABA008
- 999 __
- $a ok $b bmc $g 2000072 $s 1202699
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 148 $c 3 $d 265-276 $e 20230801 $i 1600-0447 $m Acta psychiatrica Scandinavica $n Acta Psychiatr Scand $x MED00009053
- GRA __
- $a 180449 $p CIHR $2 Canada
- GRA __
- $a 142255 $p CIHR $2 Canada
- LZP __
- $a Pubmed-20231013
